In honor of Women’s History Month, AIQ Solutions is proud to recognize some of the incredible women helping advance what is possible in medicine and improve how care is delivered to patients with cancer. 

Across clinical, technical, and partnership roles, these individuals contribute to the development and adoption of TRAQinform IQ technology. Their work supports clinicians with clearer, more reliable insights to help guide treatment decisions. 

AIQ Solutions is proud to share that we have secured a sixth patent for our AI-enabled late-stage cancer analysis technology (U.S. Patent No. 12,562,258). 

CPT code is a major milestone to scale late-stage cancer analysis technology across the healthcare system 

AIQ Solutions today announced a significant advancement in the fight against late-stage cancer. After years of rigorous clinical, regulatory, and operational work by AIQ, the American Medical Association (AMA) has approved a new Category III Current Procedural Terminology (CPT) code describing the unique output of AIQ’s TRAQinform IQ technology. This milestone will help make advanced treatment response intelligence more accessible to oncologists and the patients who need it most.